Cardiovascular risk in patients with end-stage renal disease: A potential role for advanced glycation end products

Contributions to Nephrology

Volumn 149, Issue , 2005, Pages 168-174

  Wang, Yingjie ^a   Marshall, Sally M ^a   Thompson, Michael G ^a   Hoenich, Nicholas A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; PHOSPHATIDYLSERINE; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; RISK ASSESSMENT; THROMBOCYTE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DRUG COMBINATIONS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHATIDYLSERINES; RISK ASSESSMENT; SERUM ALBUMIN;

EID: 20544442034     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000085483     Document Type: Article

References (20)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:S112-S119.
2. Jardine AG: Cardiovascular complications of renal disease. Heart 2001;86:459-466.
3. Horvat S, Jakas A: Peptide and amino acid glycation: New insights into the Maillard reaction. J Pept Sci 2004;10:119-137.
4. Wagner Z, Wittmann I, Mazak I, Schinzel R, Heidland A, Kientsch-Engel R, Nagy J: N(epsilon)-(carboxymethyl) lysine levels in patients with type 2 diabetes: Role of renal function. Am J Kidney Dis 2001;38:785-791.
5. Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF: Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 1998;22:1543-1548.
6. Walter R, Mischak H, Haller H: Haemodialysis, atherosclerosis and inflammation - Identifying molecular mechanisms of chronic vascular disease in ESDR patients. Nephrol Dial Transplant 2002;17:24-29.
7. Agalou S, Ahmed N, Dawnay A, Thornalley PJ: Removal of advanced glycation end products in clinical renal failure by peritoneal dialysis and haemodialysis. Biochem Soc Trans 2003;31:1394-1396.
8. Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, Horiuchi S: Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis 1999;142:67-77.
9. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM: N-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signalling pathways and modulate gene expression. J Biol Chem 1999;274:31740-31749.
10. Hangaishi M, Taguchi J, Miyata T, Ikari Y, Togo M, Hashimoto Y, Watanabe T, Kimura S, Kurokawa K, Ohno M: Increased aggregation of human platelets produced by advanced glycation end products in vitro. Biochem Biophys Res Commun 1998;248:285-292.
11. Daleke DL: Regulation of transbilayer plasma membrane phospholipid asymmetry. J Lipid Res 2003;44:233-242.
12. Lentz BR: Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res 2003:42:423-438.
13. Wahid ST, Marshall SM, Thomas TH: Increased platelet and erythrocyte external cell membrane phosphatidylserine in Type I diabetes and microalbuminuria. Diabetes Care 2001;24:2001-2003.
14. Henle T, Deppisch R, Beck W, Hergesell O, Hansch GM, Ritz E: Advanced glycation end products (AGE) during haemodialysis treatment: Discrepant results with different methodologies reflect heterogeneity of AGE compounds. Nephrol Dial Transplant 1999;14:1968-1975.
15. Michelson AD: Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: Methods and clinical applications. Blood Coagul Fibrinolysis 1994;5:121-131.
16. Bevers EM, Comfurius P, Dekkers DW, Zwaal RF: Lipid translocation across the plasma membrane of mammalian cells. Biochim Biophys Acta 1999;1439:317-330.
17. Pastorelli C, Veiga J, Charles N, Voignier E, Moussu H, Monteiro RC, Benhamou M: IgE receptor type I-dependent tyrosine phosphorylation of phospholipid scramblase. J Biol Chem 2001;276:20407-20412.
18. Heemskerk JW, Siljander PR, Bevers EM, Farndale RW, Lindhout T: Receptors and signalling mechanisms in the procoagulant response of platelets. Platelets 2000;11:301-306.
19. Monroe DM, Hoffman M, Roberts HR: Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002;22:1381-1389.
20. Zwaal RF, Schroit AJ: Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997;89:1121-1132.